[Adrenal function in topic corticotherapy].
It has been shown that corticosteroids for dermatological use produce an inhibition of the adrenal function, and it is considered that in our milieu these products are used without any precise indication. In this study, 29 ambulatory children from 3 to 15 years of age were selected, who were suffering from dermatoses with different degrees of extension, on whom urinary 17-ketosteroids, 17-ketogenicsteroids and serum cortisol were measured before and after non-occlusive treatment of two weeks, using 0.01 percent fluorocorticoids and controls after 24 hours and 8 days. A significant drop of the 17-keratogenicsteroids was found in patients studied at the end of the treatment, with immediate recovery. Additionally it was observed, in patients who had over 30 percent of skin area involved, that there was a decrease in serum cortisol, which persisted even 24 hours after discontinuing treatment, with normal levels in a measurement taken eight days later. It is therefore concluded that glucocorticoids applied topically are capable of inhibiting adrenal function.
D015068:17-Ketosteroids / Q000378:metabolism; D000287:Administration, Topical; D000311:Adrenal Glands / Q000502:physiology*; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D004485:Eczema / Q000188:drug therapy*; D006801:Humans; D006854:Hydrocortisone / Q000378:metabolism; D007223:Infant; D007231:Infant, Newborn; D013259:Steroids, Fluorinated / Q000008:administration & dosage*; D014820:Vitiligo / Q000188:drug therapy*
D015068:17-Ketosteroids; D013259:Steroids, Fluorinated; D006854:Hydrocortisone
La función suprarrenal en la corticoterapia tópica.